Cancer Pain Management

Cancer pain management is the assessment and relief of pain caused by a malignancy or its treatment. Pain is among the most common and feared symptoms in people with cancer, and a structured, person-centred approach to assessing its intensity, type, and impact underpins efforts to control it across the course of the disease.

Definition

Cancer pain management is the multidimensional assessment and treatment of pain arising from a tumour, its spread, or anticancer therapy, aiming to reduce pain and its impact on function and quality of life.

Scope

This entry covers the nature and classification of cancer pain, the principle of systematic assessment, the broad categories of treatment (pharmacological, interventional, and non-pharmacological), and the historical and ongoing problem of undertreatment. It is a reference overview of the field and does not provide drug regimens, doses, or individual treatment recommendations.

Core questions

• How is the intensity, type, and impact of cancer pain assessed?
• What broad categories of treatment exist for cancer pain?
• Why has cancer pain historically been undertreated?
• How does pain control relate to overall quality of life and function?

Key concepts

• Nociceptive versus neuropathic cancer pain
• Systematic pain assessment and patient self-report
• WHO approach to cancer pain relief
• Breakthrough pain
• Undertreatment of pain
• Multimodal and interventional analgesia

Mechanisms

Cancer pain arises through several mechanisms: direct tumour invasion or compression of tissues, bone, or nerves; treatment-related injury (surgery, radiotherapy, chemotherapy-induced neuropathy); and accompanying inflammatory and neuropathic processes. Pain may be predominantly nociceptive, neuropathic, or mixed, and may include episodic breakthrough pain superimposed on a background of persistent pain. Because pain is a subjective experience, assessment relies on patient self-report of intensity and character, which guides the choice between pharmacological, interventional, and non-pharmacological strategies (Fallon, 2018).

Clinical relevance

Effective pain control is central to the wellbeing of people with cancer, and surveys have documented that a substantial proportion of patients with metastatic disease experience pain that is inadequately treated (Cleeland, 1994). Clinical practice guidelines describe systematic assessment and stepwise, multimodal management of cancer pain (Paice, 2016; Fallon, 2018). This entry summarises those principles for orientation and is not a substitute for clinical judgement or for guideline-directed care.

Epidemiology

Pain is highly prevalent in cancer, particularly in advanced and metastatic disease, and remains undertreated in a meaningful share of patients; the landmark Eastern Cooperative Oncology Group survey reported that a large fraction of outpatients with metastatic cancer had pain and that many received analgesia judged inadequate for its severity (Cleeland, 1994).

Evidence & guidelines

Major bodies have issued guidelines on cancer pain, including the World Health Organization's guidance on pharmacological and radiotherapeutic management (WHO, 2018), ASCO's guideline on chronic pain in cancer survivors (Paice, 2016), and ESMO's clinical practice guidelines on managing cancer pain in adults (Fallon, 2018).

History

Modern cancer pain management was shaped in the 1980s by the World Health Organization's articulation of a stepwise approach to analgesia and by growing recognition that pain was widely undertreated. The 1994 ECOG survey crystallised the scale of undertreatment, and subsequent decades brought refined assessment tools, attention to neuropathic and breakthrough pain, and updated guidelines from WHO, ASCO, and ESMO.

Debates

Persistent undertreatment of cancer pain

Despite decades of guidelines, surveys and reviews continue to find that a notable proportion of patients receive analgesia inadequate to their reported pain, reflecting barriers at the level of patients, clinicians, and health systems.

Balancing opioid access with safety

Managing cancer pain requires adequate access to opioid analgesics while attending to risks of harm and misuse, a balance that guidelines address differently across survivorship and advanced-disease contexts.

Key figures

• Charles Cleeland
• Marie Fallon
• Judith Paice

Seminal works

• cleeland-1994
• paice-2016
• fallon-2018

Frequently asked questions

Is all cancer pain caused by the tumour itself?

No. Cancer pain can come from the tumour invading or compressing tissues, but it can also result from treatment, such as surgery, radiotherapy, or chemotherapy-induced nerve damage.

Why is cancer pain often said to be undertreated?

Studies dating back to the 1990s found that many patients with cancer pain receive analgesia inadequate to their reported severity, owing to barriers involving patients, clinicians, and health systems; this gap has been a persistent focus of guidelines.